Zobrazeno 1 - 10 of 60 pro vyhledávání: '"Félix López-Cadenas"'
3
Akademický článek
Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia
Autor: Marta Martín-Izquierdo, María Abáigar, Jesús M Hernández-Sánchez, David Tamborero, Félix López-Cadenas, Fernando Ramos, Eva Lumbreras, Andrés Madinaveitia-Ochoa, Marta Megido, Jorge Labrador, Javier Sánchez-Real, Carmen Olivier, Julio Dávila, Carlos Aguilar, Juan N Rodríguez, Guillermo Martín-Nuñez, Sandra Santos-Mínguez, Cristina Miguel-García, Rocío Benito, María Díez-Campelo, Jesús M Hernández-Rivas
Publikováno v: Haematologica, Vol 106, Iss 8 (2020)
Myelodysplastic syndromes (MDS) are hematological disorders at high risk of progression to secondary acute myeloid leukemia (sAML). However, the mutational dynamics and clonal evolution underlying disease progression are poorly understood at present.
Externí odkaz: https://doaj.org/article/b5af1325c7414ed19ff05fb9bebee8d7
Zobrazit plný text záznamu
7
Predictors of cardiovascular events and all‐cause of death in patients with transfusion‐dependent myelodysplastic syndrome
Autor: Tamara Jimenez-Solas, Agustín C. Martín-García, Teresa Gonzalez-Martinez, Elena Díaz-Peláez, Marta Alonso-Fernández-Gatta, Ana Martín-García, Félix López-Cadenas, Pedro L. Sánchez, María Díez-Campelo, Clara Sanchez-Pablo
Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
Cardiovascular disease (CVD) involves the second cause of death in low-risk myelodysplastic syndrome (MDS) population. Prospective study to characterise the CVD and to identify predictors for the combined event (CE) cardiovascular event and/or all-ca
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8db70547212e07111ef3b4d833628e49
https://doi.org/10.1111/bjh.17652
Zobrazit plný text záznamu
8
Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors
Autor: Félix López Cadenas, Laura Mezquita, María A Amores Martín, Roberto A. Escala-Cornejo, Luis Figuero-Pérez, Juan Jesús Cruz Hernández, Felipe Gómez-Caminero López, María Del Rosario Vidal Tocino, Alejandro Olivares-Hernández, Lorena Bellido Hernández
Publikováno v: Case Reports in Oncological Medicine
Case Reports in Oncological Medicine, Vol 2021 (2021)
Background. Immunotherapy represents one of the fundamental treatments in the management of some types of cancer, especially malignant melanoma. Toxicity derived from increased immune system activity can manifest in multiple organs and systems. We pr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f24bcca54d27c85e7c4133643d12ec72
https://doi.org/10.1155/2021/6631859
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje